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Abstract
Objectives: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure 
response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with focus on 
clinically relevant improvement (CRIcSLE).
Methods: Pediatric nephrology and rheumatology subspecialists (n=213) experienced in cSLE 
management were invited to define CRIcSLE and rate a total of 433 unique patient-profiles for the 
presence/absence of CRIcSLE. Patient-profiles included the cSLE core response variables [cSLE-
CRVs: global assessment of patient well-being (Patient-global), physician assessment of cSLE 
activity (MD-global), disease activity index score (here: Systemic Lupus Erythematosus Disease 
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Activity Index), urine protein-to-creatinine ratio (UPCR), Child Health Questionnaire physical 
summary score (CHQ-PhS)]. Percentage and absolute changes of these cSLE-CRVs (baseline vs. 
follow-up) were considered to develop candidate algorithms and validate their performance 
[sensitivity, specificity, area under the receiver operating characteristic curve (AUC; range: 0 −1)].
Results: Using an international consensus conference, unanimous agreement on a definition of 
CRIcSLE was achieved; cSLE expects (n=13) concurred (100%) that the preferred CHILI 
algorithm considers absolute changes of the cSLE-CRVs. After transformation to range from 0 
−100, a CHILI score of ≥54 had outstanding accuracy for identifying CRIcSLE (AUC=0.93; 
sensitivity=81.1%; specificity=84.2%); CHILI scores also reflect minor, moderate and major 
improvement for values exceeding 15, 68 and 92 (all: AUC ≥ 0.92, sensitivity: ≥93.1%; 
specificity: ≥73.4%).
Conclusions: The CHILI is a new, seemingly highly accurate index for measuring clinically 
important improvement in cSLE over time. This index is useful to categorize the degree of 
response to therapy in children and adolescent with cSLE.
Keywords
lupus; childhood-onset SLE; SLE; pediatric SLE; juvenile SLE; improvement; criteria; children; 
cSLE
INTRODUCTION
Systemic lupus erythematosus is a complex, chronic multi-system autoimmune 
inflammatory disease, with up to 20% of patients diagnosed during childhood (cSLE) (1, 2). 
When disease commences early in life rather than during adulthood, lupus has a poorer 
prognosis, particularly due to multi-organ and kidney involvement (3, 4). The course of 
cSLE is characterized by episodes of disease flares; followed by periods of improvement, 
generally due to more intensive drug therapy. There is international consensus around a core 
set of variables (cSLE-CRVs) that should be considered when assessing response to therapy 
and flare of cSLE (5, 6). Considering changes in cSLE-CRVs, a Provisional ACR/cSLE 
Flare Score can be calculated to identify patients who experienced a minor, moderate or 
severe flare of cSLE (7, 8). Likewise, percentage changes of the cSLE-CRVs are the basis 
for the Pediatric Rheumatology International Trials Organization, American College of 
Rheumatology (ACR) Provisional Criteria of Response to Therapy (9). We have previously 
shown, albeit in a rather small dataset, that the PRINTO/ACR Provisional Criteria for 
Response to Therapy and, to a lesser extent, the Systemic Lupus Responder Index are both 
very well-suited to capture major improvement of cSLE; however, both the PRINTO/ACR 
Provisional Criteria of Response to Therapy and the Systemic Lupus Responder Index 
appeared less apt to identify patients who experienced moderate or minor improvement of 
cSLE (10). At present, there are no generally accepted criteria or algorithms to measure 
various degrees of improvement with cSLE, and consensus is lacking of what constitutes 
clinically relevant improvement (CRIcSLE) in children and adolescents with cSLE. The latter 
is especially relevant because in studies of rheumatoid arthritis an ACR 20% level (ACR20) 
response, or in juvenile idiopathic arthritis an ACR 30% level (JIA-ACR30) response, 
provide such a measure of clinically relevant improvement. ACR20 and JIA-ACR30 
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responses, respectively, are regarded improvement thresholds that can support labeling of 
new medications by the Food and Drug Administration or the European Medicines Agency 
(11, 12). Prior to developing criteria, or algorithms to measure CRIcSLE, it is necessary to 
achieve consensus around a definition of CRIcSLE.
Building on prior international consensus around the cSLE-CRVs that are needed to capture 
response to therapy in cSLE (9), the objectives of this study were to define CRIcSLE, and 
develop as well as initially validate criteria to measure CRIcSLE. Further, we sought to 
measure minor, moderate and major response to therapy in cSLE.
PATIENTS AND METHODS
The overall approach to this project was based on the methodological framework 
successfully employed in pediatric rheumatology criteria development in the past (9, 13, 14), 
which is aligned with recommendations of the ACR Criteria Subcommittee and the Quality 
of Care Committee (15). As is summarized in Figure 1, an initial Delphi survey was 
conducted among 114 pediatric rheumatologists and nephrologists with expertise in cSLE 
(1) to delineate key features for judging whether a patient experienced CRIcSLE [Step 1]. 
Subsequently, participants in a Consensus Conference rated 200 Patient-Profiles [Step 2]. 
During a Consensus Conference the results of Step 1 and 2 were reviewed to support 
consensus formation around a definition of CRIcSLE [Step 3]. This was followed by a 
second round of patient-profiles sent to 200 pediatric rheumatologists and the cSLE experts 
who participated in the Consensus Conference. The resulting dataset was randomly split in a 
training-dataset and a validation-dataset [Step 4]. The training-dataset was used to develop 
candidate criteria for CRIcSLE [Step 5]. These candidate criteria were tested using the 
validation-dataset [Step 6]. As done in Step 3, agreement was achieved around a preferred 
Childhood Lupus Improvement Index (CHILI) algorithm among cSLE experts with voting 
rights who had participated in Consensus Conference [Step 7].
Step 1 – Delphi Survey regarding CRIcSLE
The 13 expert participants in the Consensus Conference and 100 of the pediatric 
rheumatologists who contributed in the development of other cSLE criteria sets (6, 8) 
received a Delphi Survey inquiring about cSLE (1) characteristics and changes of cSLE-
CRVs that would support the presence of CRIcSLE. The Delphi survey was piloted (HBR, 
PӦA). Principles and recommendations for the design and conduct of online surveys were 
followed (16).
Step 2 –PP ratings prior to the Consensus Conference
Using prospective data of cSLE patients of the CCHMC Lupus Registry (17), the PRINTO 
Lupus Cohort (6), and a multicenter North American cSLE Cohort (U01-AR5868; PI 
Brunner), we developed 1,482 unique patient-profiles. After omitting patient-profiles with 
>2 missing data elements and some patient-profiles without changes in cSLE-CRVs between 
visits, there were 433 unique patient-profiles. Missing observations of these 433 patient-
profiles were imputed using multiple imputation methods and expectation–maximization 
algorithms in computation (18–20).
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Each patient-profile provided the following patient data at the time of a baseline visit and a 
follow-up visit: [1] physician assessment of cSLE activity as measured on a visual analog 
scale (VAS) (MD-global; 0 = inactive disease; 10 = very active disease); [2] parent 
assessment of patient overall well-being, measured on a VAS (Patient-global; 0 = very poor; 
10 = very well); [3] proteinuria, measured by timed urine collection or UPCR from spot 
urine; [4] erythrocyte sedimentation rate; [5] levels of complement C3 and C4; [6] item and 
summary scores of the Systemic Lupus erythematosus Disease Activity Index (SLEDAI; 
version 2k] (21); and [7] the Child Health Questionnaire Physical summary score (version 
P50; CHQ-PhS) (5, 6). Information about complete blood counts and differential, serum 
chemistry, erythrocyte sedimentation rate, urinalysis and anti-dsDNA antibody 
concentrations were also provided.
Thirteen cSLE experts (HIB, MWB, SPA, SA, CAS, FF, BG, SEW, DML, AR, RK, TA and 
MKG) who were voting participants at a Consensus Conference were asked to rate 200 of 
the 433 patient-profiles prior to the meeting. After the Consensus Conference, these cSLE 
experts plus to 200 pediatric rheumatologists who previously participated in a similar 
patient-profiles rating exercise (6–8) were asked to each rate 50 patient-profiles which were 
randomly selected from the pool of 433 patient-profiles. Each patient-profiles rater was 
asked to assess the disease course, using the following response options: (Question A) major 
improvement; moderate improvement; minor improvement; unchanged or worse or “I do not 
have enough information to make this assessment”. Further, if a patient-profile rater 
considered improvement to be present, then he/she was asked whether improvement 
constituted CRIcSLE or not (Question B). In this context, minor improvement can be 
considered equivalent to ‘any improvement’ with cSLE. The survey source data were batch-
processed, and open source online survey software, RedCap survey, was used for response 
management and as a presentation layer (see https://www.project-redcap.org/).
The minimum number of rater responses to each patient-profile was 16, and all patient-
profiles were considered in the subsequent adjudication process. Considering that patient-
profile raters may not necessarily agree on the interpretation of the disease course of a given 
patient-profile, the “true” overall course of cSLE for a given patient-profile was adjudicated 
using the Majority-Rule, i.e. the majority of the raters of a patient-profile agreed on a given 
disease course. Other Rules calculated, including the 67%-Rule, i.e. at least 2/3 of the raters 
agreed on a given disease course. Irrespective of the Rule used, results were similar to the 
Majority-Rule. Hence, we present mainly the results from Majority Rule analyses.
Three statistical strategies were employed to develop a series of candidate criteria to 
measure CRIcSLE: (a) we considered the PRINTO/ACR Provisional Criteria of Response to 
Therapy (9) which have been previously validated to measure improvement in cSLE. 
Furthermore, we developed algorithms that considered (b) absolute change or (c) relative or 
percentage changes of the cSLE-CRVs between baseline and follow-up using multinomial 
logistic regression. Strategies (b) and (c) yield a numeric “CHILI score” (or log odds of 
improvement) calculated from the combined changes of the cSLE-CRV predictors between 
baseline and follow-up (9, 22).
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Accuracy of the PRINTO/ACR Provisional Criteria of Response to Therapy was tested using 
kappa (κ) statistics. With respect to the criterion standard (here: adjudicated disease course 
from the patient-profiles ratings), κ values can be interpreted as follows: poor agreement: κ< 
0.4; fair to good agreement: κ = 0.4– 0.75; substantial to excellent agreement: κ> 0.75. For 
each of the candidate CRIcSLE algorithms from multinomial regression analysis, diagnostic 
accuracy was assessed by receiver’s operating characteristic (ROC) curve analysis. The area 
under the ROC curve (AUC, range 0 −1) was calculated, and the diagnostic accuracy was 
considered outstanding, excellent, good, fair, and poor if the AUC was in the range of 0.9 – 
1.0, 0.81 – 0.90, 0.71 – 0.80, 0.61 – 0.70, and <0.60, respectively (23).
Based on prior consensus [Step 3], threshold CHILI scores reflect the highest conditional 
AUC among all candidate thresholds on the ROC curve, i.e. the point on the ROC curve with 
the highest precision of correctly classifying the degree of cSLE improvement level 
(CRIcSLE; minor, moderate, major,).
All analyses were done using SAS 9.4 (SAS, Cary, NC) software and SYSTAT 12 (Systat 
Software Inc., Chicago, IL) software. P-values < 0.05 were considered statistically 
significant.
Step 3 – Consensus Definition of CRIcSLEE
Participants in the Consensus Conference were experienced pediatric rheumatologists and 
nephrologists from South America, North America, Asia, and Europe with substantial 
clinical and research experience in cSLE. PRINTO leadership (NR) participated in the 
discussions during the Consensus Conference as a non-voting content expert. A priori, the 
consensus level at the consensus conference was set at 75%, i.e. comparable or even 
somewhat higher than that chosen for similar studies in the past (6, 13, 24). Using nominal 
group technique guided by an experienced moderator (BMF), the expert panel reached 
agreement around the definition of CRIcSLE. The panel also reviewed the performance of the 
Provisional PRINTO/ ACR Criteria of Response to Therapy and candidate improvement 
algorithms derived by multinomial logistic regression using PP-ratings from Step 2, 
considering the OMERACT Filter (25–27): [1] feasibility, i.e. practicability: can the items be 
measured easily?; [2] reliability, i.e. reproducibility: can the items be measured precisely?; 
[3] redundancy: are there two or more items included in the candidate criteria measuring the 
same aspect of the disease?); [4] face validity, i.e. credibility: are the criteria sensible?; [5] 
content validity, i.e. comprehensiveness: do the criteria sample all of the domains of the 
disease?; [6] criterion validity: based on AUC, do the criteria accurately approximate the 
“gold standard”, i.e. the adjudicated disease course as Majority-Rule?; [7] sensitivity and 
specificity: do the criteria effectively identify patients with CRIcSLE and/or various levels of 
improvement and distinguish them from patients who do not experienced CRIcSLE and/or 
various levels of improvement?; and [8] discriminant validity: do the criteria detect the 
smallest clinically important change?; i.e. discriminate patients with one of the following 
disease courses: CRIcSLE; minor improvement, moderate improvement, major improvement, 
unchanged or worse.
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Step 4 – Second round of Patient-Profile ratings
Besides individuals who were invited to participate in Step 1 and 2, the 433 patient-profiles 
were then sent to another 100 pediatric rheumatologists who previously participated in a 
similar study (7). Hence, a total of 213 patient-profile raters received 50 randomly selected 
patient-profiles each; formats, response options, adjudication were described in Step 2. The 
resulting dataset was divided in the sequence of acquisition into a training-dataset and a 
validation-dataset.
Steps 5 and 6 – Development and preliminary validation of the CHILI
Using the training-dataset [Step 4], we newly developed candidate algorithms to measure 
improvement (CRIcSLE, minor, moderate, major) as described in Step 2. In these algorithms, 
CRIcSLE was considered to be a special threshold score among many possible improvement 
scores. Threshold scores were transformed to range between 0 and 100. The algorithms and 
thresholds developed in the training-dataset [Step 5] were validated using the validation-
dataset to derive at preliminary CHILI criteria [Step 6].
Step 7 - Ranking of Preliminary CHILI algorithms after the Consensus Conference
The analyses from Steps 5 and 6 were presented to the Consensus Conference participants 
with voting rights. These cSLE experts were asked whether, in the setting of a clinical trial, 
(1) CRIcSLE algorithms from multinomial logistic regression were preferable to the use of 
the PRINTO/ACR Provisional Criteria for Response to Therapy; (2) absolute differences of 
the cSLE-CRVs were superior to percentage changes when measuring CRIcSLE; and; (3) 




The survey [Step 1] inquired about changes in cSLE-CRVs, signs and symptoms with 
CRIcSLE. Among the 113 pediatric rheumatologists and nephrologists approached for survey 
participation 92 responded (81%). Survey participants from different regions or less vs. 
more than 10 years of experience in treating cSLE did not differ significantly in their 
responses (data not shown). There was ≥ 80% agreement that, with CRIcSLE, the MD-global 
and/or the score of a disease activity index must be better or unchanged; and that patients 
with CRIcSLE could experience new organ involvement as long as this did not involve the 
neuropsychiatric hematological, gastrointestinal, renal, ophthalmological, or 
cardiopulmonary organ systems. The initial ratings of 200 patient-profiles provided 
additional data regarding the measurement of the CRIcSLE (see Supplemental table 1 for 
adjudication results). After review of this information during the Consensus Conference 
(Step 3), there was 100% agreement for the following consensus definition of CRIcSLE: “a 
clinically relevant improvement has occurred in a child with lupus if there are reduced signs 
of disease from active lupus. Although there may not be improvement of lupus activity in all 
organ systems, there cannot be increased lupus activity in a major organ system, i.e. 
neuropsychiatric hematological, gastrointestinal, renal, ophthalmological, or 
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cardiopulmonary organ systems. Patient symptoms will be at least stable, and 
immunosuppressive therapy should be unchanged or decreased”. Further, cSLE experts 
concluded that further testing of the PRINTO/ACR Provisional Criteria of Response to 
Therapy in cSLE was warranted, and that a multinomial logistic regression modeling should 
be pursued to measure CRIcSLE with threshold choice at the statistical optimal point on the 
AUC (both ≥92 % agreement).
Post Consensus Conference patient profile ratings
As part of Step 4, the 433 patient-profiles were sent to 213 patient-profile raters. The 
response rate was 91% (194/213, see Appendix 1), and all 433 patient-profiles qualified for 
adjudication. The resulting dataset was split in a training-dataset (200 patient-profiles) and a 
validation-dataset (n=233). Baseline characteristics of the patients represented in these 
datasets are summarized in Table 1.
Using the Majority Rule, there were 95 (47.5%) patient-profiles without CRIcSLE and 105 
patient-profiles (52.5%) with CRIcSLE in the training-dataset. Among patient-profiles 
adjudicated to reflect CRIcSLE, 83% were considered to represent moderate or major 
improvement of cSLE, while 99% of patient-profiles without CRIcSLE were adjudicated to 
reflect at most minor improvement of cSLE.
Performance of individual cSLE-CRVs to measure CRIcSLE
Based on univariate logistic regression in the training-dataset (Table 2), absolute changes 
and percentage (or relative) changes of the cSLE-CRVs had similar discriminative properties 
to detect CRICSLE (Table 2). However, only absolute changes of the UPCR (P< 0.001) 
between baseline and follow-up but not percentage changes (p=0.132) significantly differed 
among patients with vs. without CRICSLE. Different from the other cSLE-CRVs but 
irrespective of the type of change (absolute, relative) considered, the UPCR had only fair 
accuracy (AUC≤0.67) in capturing CRICSLE. Individually, the MD-global and the SLEDAI 
had the highest accuracy (both AUC≥0.90) for identifying the CRICSLE status.
Performance of the PRINTO/ACR Provisional Criteria of Response to Therapy to measure 
CRIcSLE
As shown in Table 3 and Supplemental Table 2, in both the training-dataset or validation-
dataset, the PRINTO/ACR Provisional Criteria for Response to Therapy had at most fair 
accuracy for capturing CRICSLE status (k ≤0.3 for Majority Rule; κ≤0.43 for 67% Rule). 
The same was also true for measuring various levels of improvement (all: κ<0.34 for 
Majority Rule and 67% Rule).
Development of the CHILI to measure CRIcSLE
As part of Step 5 analyses (Table 4), we used multinomial regression to generate candidate 
algorithms that considered the cSLE-CRVs that were identified to relevant for capturing 
improvement of cSLE (6, 22). Irrespective of the type of change, i.e. absolute or percentage 
differences of the cSLE-CRVs between baseline and follow-up, algorithms were similar in 
their accuracy (AUC) to measure CRIcSLE. For example, using the algorithm that considered 
absolute changes of the cSLE-CRVs, a logit score 0.16 or, after transformation to a scale 
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between 0 and 100, a CHILI score 54 was 89.5% sensitive and 92.6% specific for capturing 
CRICSLE status correctly (AUC= 0.97) in the development-dataset. When considering 
percentage changes of the cSLE-CRVs between visits in the algorithm instead, a CHILI 
score of 60 had similar measurement properties (AUC=0.96, sensitivity=87.6%, 
specificity=92.6) for capturing CRICSLE status (Figure 2, panel a).
Initial validation of the CHILI algorithms
Algorithms considering absolute changes rather than percentage changes of the cSLE-CRVs 
were similarly robust, i.e. they maintained their accuracy (AUC) similarly well the 
validation-dataset. Using the model parameters and threshold scores obtained from the 
training-dataset, the AUC of discrimination between patients who had CRIcSLE as compared 
to those who did not was 0.93 (Figure 2, panel a). Hence, a CHILI score of 54 (absolute 
changes of the cSLE-CRVs are considered) represents the optimal threshold score based on 
the training-dataset. This CHILI score of 54 is 81.1% sensitive and 84.2% specific for 
CRIcSLE in the validation-dataset.
Use of the CHILI to identify minor, moderate and major response to cSLE therapy
As is summarized in Table 4 and in Figure 2, Panels b-d, the CHILI algorithms developed 
and validated to measure CRICSLE were also excellent in discriminating patients with 
various levels of improvement (minor, moderate, major) between baseline and follow-up. 
Again, algorithms considering absolute differences and percentage differences of the cSLE-
CRVs between baseline and follow-up performed similarly well in both the trainings dataset 
and the validation dataset.
Ranking of the candidate CHILI algorithms
The results of the performance of the PRINTO/ACR Provisional Criteria for Response to 
Therapy, CHILI algorithms considering percentage and CHILI algorithms considering 
absolute changes of the cSLE-CRVs were presented to the Consensus Conference 
participants with voting rights. There was consensus (100%) that the CHILI algorithms were 
preferable to the PRINTO/ACR Provisional Criteria for Response to Therapy to measure 
CRIcSLE as well as various levels of improvement in clinical trials of cSLE. Further, CHILI 
algorithms using absolute changes were favored over those using percentage changes of the 
cSLE-CRVs, given their ease of use. Although scaling to a range between 0 −100 was 
favored, there were some concerns about that transformation might be mathematically 
challenging.
DISCUSSION
This international study investigated clinically important improvement of children with 
cSLE. In addition to a consensus definition of CRIcSLE, we developed and initially 
validated the CHILI to serve as provisional criteria to measure CRIcSLE. A composite 
measure to capture CRIcSLE is necessary because there is no single sign, clinical test, or 
patient symptom that is adequately sensitive and simultaneously specific to the presence of 
CRIcSLE. Further, we confirm that the CHILI is able to accurately describe the degree of 
cSLE improvement.
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Several pediatric rheumatology response measures, such as the JIA-ACR30 Criteria to 
capture response to therapy with JIA, consider relative – or percentage – changes of core 
response variables. While CHILI algorithms using percentage and absolute changes 
performed similarly in terms of accuracy, sensitivity and specificity at the proposed 
threshold scores, we consider CHILI scores calculated from absolute changes of the cSLE-
CRVs to be easier to compute, hence preferable. This is in keeping with the recently 
published ACR Provisional Criteria of Global Flare of cSLE (7). Indeed more complex 
mathematical maneuvers beyond addition and multiplication are avoided which is different 
from the DAS28 score which includes a square root calculation, for example (28). For 
reasons of scaling, we transformed the CHILI scores to range between 0 – 100, with higher 
scores reflecting a larger degree of improvement. Whether such mathematical transformation 
maneuvers improve the ease of use of the CHILI will need to be studied in the future.
Different from the ACR Provisional Criteria of Global Flare of cSLE (7), the CHILI 
considers patient perspective more comprehensively, specifically changes in patient overall 
well-being and physical function (CHQ-PhS) are included in the algorithm. This is in 
keeping with the results of earlier discussions of the how to capture response to therapy in 
cSLE (6, 8).
Currently, the Systemic Lupus Responder Index is the principal outcome measure used in 
clinical trials of adults with SLE. We have shown that the PRINTO/ACR Provisional Criteria 
for Response to Therapy in cSLE (9) are more accurate than the Systemic Lupus Responder 
Index in capturing improvement with cSLE (10). In this study, we confirmed that the 
PRINTO/ACR Provisional Criteria of Response to Therapy seems to have at best fair 
accuracy for capturing the true course of cSLE, including CRIcSLE. Different from the 
CHILI, in the PRINTO/ACR Provisional Criteria for Response to Therapy, all cSLE-CRVs 
changes are considered equally (same percentage changes) relevant for measuring response 
to therapy. However, from a measurement point of view, supported by the consensus 
definition for CRIcSLE, and our univariate analysis, the cSLE-CRVs have differential 
importance to clinicians when judging the disease course of a child with cSLE (10). Taken 
together, the PRINTO/ACR Provisional Criteria of Response to Therapy – and by extension 
the Systemic Lupus Responder Index – can be used in clinical trials of cSLE but likely 
require larger sample sizes than when using the CHILI to capture response to therapy.
A limitation of our study might be that we were unable to test whether consideration of the 
British Isles Lupus Activity Group index (BILAG) index (30) or other disease activity 
indices instead of the SLEDAI as a measure of cSLE activity, would have allowed us to 
identify cSLE patients who experienced CRIcSLE accurately. Indeed, the cSLE-CRVs do 
not specify which validated measures of cSLE activity is considered for the assessment of 
patients’ response to therapy (9). We used the SLEDAI, given its ease of use and widespread 
acceptance around the world. Additional research will be required to assess whether other 
disease activity index scores can be used interchangeably. Further, we did not provide 
patient-profile raters with consensus definitions of what constitutes minor, moderate or 
major improvement. Nonetheless, the accuracy of the CHILI algorithm performed well in 
the datasets used in this study. Lastly, we focused on the Majority Rule to adjudicate the 
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disease course presented in the various patient-profiles, which might have introduced bias. 
However, the 67% Rule yielded comparable results for the CHILI
The ACR has outlined a series of validation steps necessary before new criteria are to be 
widely used for clinical care or research (15, 31). One step is to use data from clinical trials 
for developing response criteria. However, such data from interventions that impact cSLE 
activity presently are unavailable. Thus, we used the patient-profiles raters’ perception of the 
course of cSLE instead. Given the prospective character of our data and the expertise of the 
PP-raters, we consider the quality of the training-dataset and the validation-dataset to be 
high; and the number of PPs to assess CRIcSLE yielded a robust CHILI.
In summary, a methodologically stringent process has been employed to develop a novel 
index to measure global improvement or response to therapy in cSLE. This Provisional 
CHILI instrument can be used to help identify children with cSLE who have experienced a 
clinically relevant improvement and to categorize the degree of improvement as minor, 
moderate, or major. However, additional testing in independent data-sets is required to 
confirm the performance characteristics of the CHILI when used in cSLE.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• International consensus regarding a definition of clinically relevant 
improvement of children and adolescents with lupus has been achieved.
• The PRINTO/ACR Provisional Criteria for Response to Therapy of children 
with lupus have only fair accuracy for capturing clinically relevant 
improvement of children with lupus as judged by physicians.
• Using strategies for the development of response measures in line with those 
suggested by the ACR, we newly developed and initially validated highly 
accurate criteria to measure clinically relevant improvement of children and 
adolescents with lupus.
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Table1:
Description of 433 Patient-Profiles used in Step 4 using the Majority Rule
Patient Profile details
¶ Training-dataset (N=200) Validation-dataset (M=233)
Baseline visit Follow-up visit Baseline visit Follow-up visit
SLEDAI items
*
 Seizure 3 (1.5%) 0 (0.0%) 4 (1.7%) 0 (0.0%)
 Psychosis 4 (2.0%) 0 (0.0%) 5 (2.2%) 0 (0.0%)
 Organic brain syndrome 7 (3.5%) 1 (0.5%) 9 (3.9%) 2 (0.9%)
 Visual Disturbance 4 (2.0%) 1 (0.5%) 4 (1.7%) 1 (0.4%)
 Cranial nerve involvement 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Lupus headaches 12 (6.0%) 2 (1.0%) 15 (6.4%) 2 (0.9%)
 Cardiovascular accidents 1 (0.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Vasculitis 27 (13.5%) 6 (3.0%) 25 (10.7%) 6 (2.6%)
 Arthritis 80 (40.0%) 22 (11.0%) 96 (41.2%) 19 (8.2%)
 Myositis 4 (2.0%) 2 (1.0%) 9 (3.9%) 4 (1.7%)
 Urinary casts 30 (15.0%) 9 (4.5%) 38 (16.3%) 7 (3.0%)
 Hematuria 71 (35.5%) 31 (15.5%) 100 (42.9%) 30 (12.9%)
 Proteinuria 90 (45.0%) 49 (24.5%) 82 (35.2%) 52 (22.3%)
 Leukocyturia 44 (22.0%) 20 (10.0%) 66 (28.3%) 20 (8.6%)
 Rash 81 (40.5%) 26 (13.0%) 100 (42.9%) 27 (11.6%)
 Alopecia 42 (21.0%) 13 (6.5%) 50 (21.5%) 15 (6.4%)
 Mucosal ulcers 42 (21.0%) 9 (4.5%) 50 (21.5%) 12 (5.2%)
 Pleurisy 8 (4.0%) 2 (1.0%) 15 (6.4%) 4 (1.7%)
 Pericarditis 8 (4.0%) 1 (0.5%) 14 (6.0%) 0 (0.0%)
 Low complement levels 154 (77.0%) 116 (58.0%) 174 (74.7%) 128 (54.9%)
 Positive anti-dsDNA antibodies 155 (77.5%) 109 (54.5%) 175 (75.1%) 119 (51.1%)
 Fever 42 (21.0%) 5 (2.5%) 46 (19.7%) 3 (1.3%)
 Thrombocytosis 12 (6.0%) 2 (1.0%) 13 (5.6%) 4 (1.7%)
 Leukopenia 27 (13.5%) 7 (3.5%) 39 (16.7%) 8 (3.4%)
 SLEDAI summary score
** 14.0 ± 8.5 /
13.0 (2.0, 39.0)
5.9 ± 5.1 /
4.0 (0.0, 31.0)
14.2 ± 8.1 /
13.0 (0.0, 39.0)




 ESR 48.8 ± 35.2 /40.0 (1.0, 180)
25.5 ± 18.9 /
21.0 (2.0, 103)
47.6 ± 37.8 /
40.0 (1.0, 180)
24.3 ± 17.2 /
21.0 (1.0, 101)
 UPCR 1.3 ± 2.2 /0.3 (0.0, 13.2)
0.5 ± 1.1 /
0.2 (0.0, 7.8)
1.2 ± 2.3 /
0.2 (0.0, 13.2)
0.5 ± 1.2 /
0.2 (0.0, 7.8)
Other assessments
 MD-global 4.2 ± 2.9 /4.1 (0, 10)
1.7 ± 2.1 /
0.8 (0, 10)
5.0 ± 2.6 /
5.0 (0, 10)
1.8 ± 1.8 /
1.1 (0, 8.6)
 Patient-global 3.0 ± 3.0 /1.9 (0, 10)
1.4 ± 2.0 /
0.6 (0, 10)
4.8 ± 3.3 /
5.0 (0, 10)
3.3 ± 3.5 /
1.7 (0, 10)
 CHQ-PhS 36.8 ± 15.5 /40.4 (1.0, 58.7)
45.4 ± 11.5 /
49.4 (5.5, 59.7)
36.9 ± 14.7 /
40.3 (1.0, 58.7)
44.6 ± 11.7 /
48.4 (10.3, 59.7)
*
Values are n (% N) or
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**
mean+SD / Median (Min, Max);
¶
MD-global: physician assessment of cSLE Activity as measured on a visual analog scale (VAS), 0 = inactive disease, 10 = very active disease; 
Patient-global: parent assessment of patient overall well-being, measured on a VAS (Patient-global;0 = very poor; 10 = very well; UPCR: 
proteinuria, measured by timed urine collection or spot protein to creatinine ratio; ESR: erythrocyte sedimentation rate; CHQ-PhS: Child Health 
Questionnaire (parent version P50) Physical Function Summary score
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